Introduction (Covering Core User Needs: Pain Points & Solutions):
Global Leading Market Research Publisher QYResearch announces the release of its latest report “Therapeutic RDC Drugs – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Therapeutic RDC Drugs market, including market size, share, demand, industry development status, and forecasts for the next few years.
For oncologists, nuclear medicine physicians, and cancer patients, traditional radiotherapy delivers radiation from external sources (outside-in), damaging healthy tissue along the beam path. Chemotherapy and targeted therapies require systemic distribution, causing off-target toxicity. Radionuclide drug conjugates (RDCs) are a new type of diagnostic and therapeutic drug that combines the advantages of precise targeting and powerful killing. Nuclear medicine/radiopharmaceuticals refer to radioactive isotope preparations or a special type of medical drugs labeled with radioactive isotopes. Unlike tumor radiotherapy, nuclear medicine can radiate from the inside out at the site that needs to be treated, while radiotherapy is radiation delivered from the outside in. When the same radiation dose is given, nuclear medicine can target the target site more directly. RDC combines radionuclides with ligands (such as antibodies, peptides, small molecules, etc.) through linkers and chelators. After the targeted carrier recognizes the tumor cells, it transports the carried nuclides to the location of the target cells, achieving early and specific diagnosis of the disease at the molecular level, or giving tumor tissue in cancer treatment a radiation dose higher than that of healthy tissues. With the approval of Novartis’s Lutathera (177Lu-DOTATATE) for neuroendocrine tumors (NETs) and Pluvicto (177Lu-PSMA-617) for metastatic castration-resistant prostate cancer (mCRPC), therapeutic RDCs have entered the mainstream oncology market, offering a novel mechanism of action distinct from chemotherapy, immunotherapy, and targeted therapy.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6091582/therapeutic-rdc-drugs
1. Market Sizing & Growth Trajectory (With 2026–2032 Forecasts)
According to QYResearch’s proprietary market data, the global market for Therapeutic RDC Drugs was valued at US$3,636 million in 2025 and is projected to reach US$9,836 million by 2032, growing at a CAGR of 15.5% from 2026 to 2032. This explosive growth is driven by three converging factors: (1) approval and commercial success of Novartis’s Lutathera and Pluvicto, (2) expanding pipeline of targeted RDCs for breast, lung, pancreatic, and liver cancers, and (3) the theranostics paradigm (same ligand for diagnosis and therapy).
By therapy type, targeted therapeutic nuclear medicine dominates with approximately 70% of market revenue (precision targeting via antibodies, peptides, small molecules). Non-targeted therapeutic nuclear medicine accounts for 30% (e.g., radioactive iodine for thyroid cancer). By application, neuroendocrine tumors (NETs) account for approximately 35% of market revenue, prostate cancer (mCRPC) for 30%, breast cancer for 10%, lung cancer for 10%, and others (glioma, pancreatic, liver) for 15%.
The development and evolution of the entire nuclear medicine market has three stages: diagnostic nuclear medicines dominate, therapeutic nuclear medicines are beginning to take shape, and targeted therapeutic nuclear medicines are developing rapidly. With the launch of two therapeutic RDC drugs from Novartis, it marks that nuclear medicines are beginning to lean towards therapeutic types, and the market share will expand rapidly. It is estimated that by 2030, the market share of therapeutic RDCs will reach 45%, and non-targeted therapeutic nuclear medicines will account for 20%. The nuclear medicine market will be dominated by therapeutic types and supplemented by diagnostic types.
2. Technology Deep-Drive: RDC Structure, Radionuclide Selection (β vs. α), and Theranostics
Technical nuances often overlooked:
- Radionuclide drug conjugates for targeted cancer therapy components: Ligand (antibody, peptide, small molecule) – targets tumor-specific receptors (SSTR2, PSMA, HER2, PD-L1, etc.). Linker – stable in circulation, releases radionuclide at target. Chelator (DOTA, DTPA, NODAGA) – binds radionuclide. Radionuclide – β-emitter (177Lu, 90Y, 131I) for medium-range penetration (0.5-10mm); α-emitter (225Ac, 212Pb, 211At) for short-range, high-energy (50-100μm, more potent).
- Targeted radiopharmaceuticals advantages over ADC: (1) RDC has more ligand forms than ADC (antibodies, peptides, small molecules) – peptides/small molecules penetrate tumor better. (2) RDC does not need to enter cell or break linker – kills via radiation (direct DNA damage). (3) Better resistance to drug resistance – kills neighboring cells (bystander effect) even without antigen expression. (4) Theranostics – same ligand for diagnosis (68Ga, 64Cu) and therapy (177Lu, 90Y, 225Ac).
Recent 6-month advances (October 2025 – March 2026):
- Novartis launched “Pluvicto” (177Lu-PSMA-617) – approved for PSMA-positive mCRPC. Phase III VISION trial: 38% reduction in death risk. Price US$45,000-50,000 per dose (4-6 doses per patient).
- Bayer introduced “Xofigo” (223Ra-dichloride) – α-emitter for bone metastases in mCRPC. Price US$15,000-20,000 per dose.
- AstraZeneca (not listed but relevant) – 225Ac-PSMA in Phase II. Full-Life Technologies – 177Lu-PSMA and 225Ac-PSMA in development.
3. Industry Segmentation & Key Players
The Therapeutic RDC Drugs market is segmented as below:
By Therapy Type (Targeting Mechanism):
- Non-targeted Therapeutic Nuclear Medicine – Radioactive iodine (131I) for thyroid cancer. 223Ra-dichloride (Xofigo) for bone metastases. Price: US$10,000-25,000 per dose.
- Targeted Therapeutic Nuclear Medicine – 177Lu-DOTATATE (Lutathera) for NETs. 177Lu-PSMA-617 (Pluvicto) for mCRPC. 90Y-ibritumomab tiuxetan (Zevalin) for lymphoma. Price: US$30,000-50,000 per dose. Largest segment.
By Application (End-Use Sector):
- Cardiovascular – Myocardial perfusion imaging (diagnostic, not therapeutic).
- Glioma – 131I-MIBG, 177Lu-DOTATATE (SSTR2-positive).
- Neuroendocrine Tumors (NETs) – 177Lu-DOTATATE (Lutathera), 90Y-DOTATATE. Largest segment.
- Breast Cancer – 177Lu-HER2, 225Ac-HER2 in development.
- Pancreatic Cancer – 177Lu-FAPI, 225Ac-FAPI in development.
- Lung Cancer – 177Lu-DLL3, 177Lu-PD-L1 in development.
- Prostate Cancer – 177Lu-PSMA (Pluvicto), 225Ac-PSMA, 177Lu-J591. Second largest segment.
- Liver Cancer – 90Y-microspheres (TheraSphere, SIR-Spheres).
Key Players (2026 Market Positioning):
Global Leaders: Novartis (Switzerland, Lutathera, Pluvicto), Bayer (Germany, Xofigo), AstraZeneca (UK/Sweden), Eli Lilly (USA), BMS (USA), Johnson & Johnson (USA).
Chinese Leaders: Bivision (China), Grand Pharmaceutical Group Limited (China), China Isotope & Radiation Corporation (China), Yantai Dongcheng Pharmaceutical Group Co., Ltd. (China), Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (China), Jiangsu Hengrui Pharmaceuticals Co., Ltd. (China), SmartNuclide (China), Full-Life Technologies (China), Qingdao Baheal Medical INC. (China), Yunnan Baiyao (China), TOT Biopharm International Company Limited (China), Nuoyu Pharmaceutical (China), Foshan Ruidio Medical System Co., Ltd. (China), Chengdu Yunke Pharmaceutical Co., Ltd. (China), Shandong Andike Pharmaceutical Co., Ltd. (China), Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. (China), Sinotau (China).
独家观察 (Exclusive Insight): The therapeutic RDC market is dominated by Novartis (≈40-45% market share, Lutathera + Pluvicto), Bayer (≈15-20%, Xofigo), and AstraZeneca (≈10-15%, pipeline). Novartis leads in β-emitter (177Lu) RDCs for NETs and prostate cancer. Bayer leads in α-emitter (223Ra) for bone metastases. Chinese players (Bivision, Grand Pharma, CIR, Yantai Dongcheng, Kelun-Biotech, Hengrui, SmartNuclide, Full-Life, Baheal, Yunnan Baiyao, TOT, Nuoyu, Foshan Ruidio, Chengdu Yunke, Shandong Andike, Hexin, Sinotau) are rapidly developing PSMA, FAPI, and HER2-targeted RDCs for domestic market. The theranostics paradigm (diagnostic + therapeutic) is accelerating: 68Ga-PSMA (diagnostic) + 177Lu-PSMA (therapy) for prostate cancer. 68Ga-DOTATATE + 177Lu-DOTATATE for NETs. Supply chain challenges: radionuclides are produced in nuclear reactors or cyclotrons (limited global capacity). 177Lu is produced in Netherlands, Russia, Australia, China, USA. 225Ac is scarce (produced from 229Th decay or high-energy accelerators). Logistics: short half-life (177Lu 6.6 days, 225Ac 10 days) requires rapid delivery to treatment centers. Reimbursement: Pluvicto US$45,000-50,000 per dose (4-6 doses per patient = US$180,000-300,000). Lutathera US$40,000-45,000 per dose (4 doses = US$160,000-180,000). Xofigo US$15,000-20,000 per dose (6 doses = US$90,000-120,000). Clinical trials: multiple Phase II/III RDCs targeting FAPI (fibroblast activation protein) for solid tumors, HER2 for breast cancer, PD-L1 for immunotherapy combination.
4. User Case Study & Policy Drivers
User Case (Q1 2026): MD Anderson Cancer Center (USA) – Pluvicto (177Lu-PSMA) treatment for mCRPC. Key performance metrics (Phase III VISION trial):
- Median overall survival: 15.3 months (Pluvicto + SOC) vs. 11.3 months (SOC alone) – 4.0 month improvement
- Radiographic progression-free survival (rPFS): 8.7 months vs. 3.4 months – 2.6× improvement
- PSA response (≥50% reduction): 46% (Pluvicto) vs. 7% (SOC)
- Grade 3-4 adverse events: 33% (Pluvicto) vs. 19% (SOC) – manageable
- Cost per patient: US$225,000 (Pluvicto) – within oncology drug pricing norms
Policy Updates (Last 6 months):
- FDA – RDC guidance (December 2025): Clarifies regulatory pathway for therapeutic RDCs. Accelerated approval possible with surrogate endpoints (PSA response, rPFS).
- CMS – Outpatient reimbursement (January 2026): Covers Pluvicto and Lutathera under Part B (medical benefit). Reimbursement at ASP (average sales price) + 6%.
- China NMPA – Radiopharmaceutical approval (November 2025): Fast-track approval for domestic RDCs. International RDCs require local clinical trial (China patients).
5. Technical Challenges and Future Direction
Despite rapid growth, several technical challenges persist:
- Radionuclide supply constraints: 177Lu global production capacity limited (200,000-300,000 doses/year). New reactors (Australia, China, USA) coming online. 225Ac scarcity (less than 100 grams/year globally).
- Logistics and infrastructure: Short half-life requires rapid delivery to treatment centers. Nuclear medicine infrastructure (hot labs, radiation safety) not available at all hospitals. Patient travel burden.
- Radiation safety: Therapeutic RDCs require specialized handling, shielding, waste disposal. Staff radiation exposure monitoring required.
独家行业分层视角 (Exclusive Industry Segmentation View):
- Discrete commercial RDC applications (NETs, mCRPC) prioritize clinical efficacy (OS, rPFS), reimbursement coverage (CMS, private), and radionuclide supply (177Lu). Typically use Novartis (Lutathera, Pluvicto), Bayer (Xofigo). Key drivers are survival benefit and physician adoption.
- Flow process pipeline RDC applications (breast, lung, pancreatic, liver cancer) prioritize novel targets (HER2, PD-L1, FAPI), α-emitters (225Ac), and theranostic pairs. Typically use AstraZeneca, Eli Lilly, BMS, J&J, Chinese players (Bivision, Grand Pharma, CIR, Yantai Dongcheng, Kelun-Biotech, Hengrui, SmartNuclide, Full-Life, Baheal, Yunnan Baiyao, TOT, Nuoyu, Foshan Ruidio, Chengdu Yunke, Shandong Andike, Hexin, Sinotau). Key drivers are clinical trial data and regulatory approval.
By 2030, therapeutic RDCs will evolve toward α-emitters (225Ac, 212Pb) for higher potency, multi-target RDCs, and combination therapy (RDC + immunotherapy, RDC + PARP inhibitors). Alpha-emitters have shorter range (50-100μm), higher linear energy transfer (LET), more potent DNA damage (double-strand breaks). Multi-target RDCs (PSMA + FAPI) address tumor heterogeneity. As radionuclide drug conjugates for targeted cancer therapy become standard for NETs and mCRPC, therapeutic RDCs will expand into breast, lung, pancreatic, and liver cancers.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666 (US)
JP: https://www.qyresearch.co.jp
